Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp.

February 09, 2010 08:30 ET

Stem Cell Therapeutics Corp. Announces the Third and Final Positive Review by the Data Safety and Monitoring Board for the Modified REGENESIS Phase IIb Stroke Trial

CALGARY, ALBERTA--(Marketwire - Feb. 9, 2010) - Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:SSS) announced today it has been advised by the Data Safety Monitoring Board ("DSMB") that its third and final regularly scheduled safety analysis has been completed and the DSMB has recommended for the Phase IIb acute ischemic stroke trial to continue as per protocol.

Dr. Alan Moore, President and CEO, commented as follows:

"Since the initiation of the modified REGENESIS Phase IIb acute ischemic stroke study, 96 patients have been enrolled in the study. We continue to anticipate that patient enrollment for the Phase IIb stroke trial will be complete by the end of Q1 2010 and for top-line data to be available after the 90-day patient assessment review period is complete, approximately by the end of Q2 2010." 

About the Data Safety Monitoring Board ("DSMB"): The DSMB is a group of independent clinical experts that review the ongoing conduct of a clinical trial to ensure continuing patient safety. The mandate of SCT's DSMB is to provide objective, independent monitoring of patient safety during the Phase IIb acute ischemic stroke trial. This review was the third of three formal meetings scheduled to occur over the duration of the Phase IIb stroke trial.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information